At ACADIA, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need SAN DIEGO & MELBOURNE, Australia --(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S.
- Full Year 2019 Net Sales Grew to $339.1 Million , a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million - On-Track to Submit Supplemental New Drug Application for Dementia-Related Psychosis in Summer 2020 SAN DIEGO --(BUSINESS WIRE)--Feb.
SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40 th Annual Health Care Conference in Boston on Monday, March 2, 2020 , at 2:10 p.m. Eastern Time . A live webcast of ACADIA’s presentation will be
There are currently no events scheduled.